Form 4: OnKure Therapeutics Chief Scientific Officer Granted Stock Options

OnKure Therapeutics' Chief Scientific Officer, Dylan Hartley, was granted 45,000 stock options on January 27, 2025, which vest monthly starting February 27, 2025.

Summary

• Dylan Hartley, the Chief Scientific Officer of OnKure Therapeutics, was granted 45,000 employee stock options.
• The options have an exercise price of $5.19 per share.
• The grant date was January 27, 2025.
• The options vest monthly, with 1/48th of the shares vesting each month starting February 27, 2025, contingent on continued service.
• The options expire on January 26, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

The granting of stock options is a common practice in the biotechnology industry to incentivize key personnel and align their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often used to attract and retain talent.
• The vesting schedule of 1/48th per month is a typical structure to ensure continued service and commitment from the executive.
• The exercise price of $5.19 is specific to OnKure's valuation and is not directly comparable to other companies without further context.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the executive's performance leads to company growth.
• The vesting schedule encourages the executive's long-term commitment to the company.

Key Dates

Keywords

stock options, executive compensation, OnKure Therapeutics, Dylan Hartley, vesting, equity